Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: Descriptive meta-analysis of post-marketing study data

International Journal of Hematology

Volumn 84, Issue 2, 2006, Pages 158-165

  Yoshioka, A ^a   Fukutake, K ^b   Takamatsu, J ^c   Shirahata, A ^d  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Hemophilia A; Operation; Previously treated patients; Recombinant factor VIII (Kogenate); Tooth extraction

Indexed keywords

ANTIBODY; BABY HAMSTER KIDNEY PROTEIN ANTIBODY; BLOOD CLOTTING FACTOR 8 ANTIBODY; MOUSE IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG;

ADULT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; ASSAY; BETHESDA ASSAY; BLEEDING; BLOOD SAMPLING; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEMOPHILIA A; HEMOSTASIS; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PHASE 3 CLINICAL TRIAL; POSTMARKETING SURVEILLANCE; STOMACH DISCOMFORT; THORAX PAIN; TOOTH EXTRACTION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANIMALS; AUTOANTIBODIES; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; CRICETINAE; DOGS; DRUG CONTAMINATION; FACTOR VIII; FOLLOW-UP STUDIES; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN G; INFANT; MIDDLE AGED; TIME FACTORS;

EID: 33748425733     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06019     Document Type: Article

References (27)

1. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature. 1984;312:326-330.
2. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature. 1984;312:330-337.
3. Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A: Recombinant Factor VIII Study Group. N Engl J Med. 1990;323:1800-1805.
4. Yoshioka A. Advances in hemophilia and other coagulation disorders: recombinant factor VIII preparations. Int J Pediatr Hematol Oncol. 1994;1:491-497.
5. Fukui H, Yoshioka A, Shima M, et al. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A. Int J Hematol. 1991;54:419-427.
6. Fukui H, Mori K, Ishikawa M, et al. A long-term, multicenter clinical study of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A [in Japanese]. Nihon Yuketsu Gakkai Zasshi. 1991;37:593-604.
7. Yoshioka A, Fukutake K, Takamatsu J, et al. Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A. Int J Hematol. 2003;78:467-474.
8. Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors [letter]. Thromb Diath Haemorrh. 1975;34:869-872.
9. Shima M, Sawamoto Y, Nakai H, et al. Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII: Kogenate Japanese Clinical Study Group. Int J Hematol. 1995;62:35-43.
10. Ehrenforth S, Kruetz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992;339:594-598.
11. Addiego J, Kasper C, Abildgaard C, et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet. 1993;342:462-464.
12. Ljung R, Petrini P, Lindgren A, et al. Factor VIII and factor IX inhibitor in haemophiliacs. Lancet. 1992;339:1550-1551.
13. deBiasi R, Rocino A, Papa ML, et al. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost. 1994;71:544-547.
14. Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of haemophilia A. N Engl J Med. 1990;323:1800-1805.
15. Bray GL, Gomperts ED, Courter S, et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy and inhibitor risk in previously untreated individuals with hemophilia A. Blood. 1994;83:2428-2435.
16. Lusher JM, Spira J, Rodriguez D. A four-year update of safety and efficacy of an albumin-free formulated B-domain deleted factor VIII (BDD rFVIII, rVIIISQ) in previously untreated severe hemophilia A patients. Thromb Haemost. 1999;82:1493.
17. Abe T, Igata A, Ikematsu S, et al. Multicenter clinical effect of heat-treated factor VIII (CP-8) preparation for patients with hemophilia A [in Japanese]. Rinshio to Kenkyu. 1985;62:3640-3659.
18. Fujimaki M, Tanaka A, Fukutake K, et al. Clinical evaluation of recombinant factor VIII (BL-160) in patients with hemophilia A [in Japanese]. Nihon Kessen Shiketsu Gakkaishi. 1993;4:179-188.
19. Fujimaki M, Goto M, Miyazaki T, et al. Clinical study of FVIII concentrate highly purified by monoclonal antibodies to FVIII(RCG-11) [in Japanese], Kiso to Rinsho. 1992;26:299-319.
20. McMillan C, Shapiro S, Whitehurst D, et al. The natural history of factor VIII C inhibitors in patients with hemophilia A. A national cooperative study II. Observations on the initial development of factor VIII C inhibitors. Blood. 1988;71:344-348.
21. White GC, Courter S, Bray GL, et al. A multicenter study of recombinant factor VIII (RecombinateH) in previously treated patient with hemophilia A. Thromb Haemost. 1997;77:660-667.
22. Seremetis S, Lusher JM, Abildgaard CF, et al. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. Haemophilia. 1999;5:9-16.
23. Lusher JM, Lee CA, Kessler CM, Bedrosian CL, for the ReFacto Phase 3 Study Group. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia. 2003;9:38-49.
24. Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci. 1998;19:139-48.
25. Smith MP, Giangrande P, Pollman H, et al. A postmarketing surveillance study of safety and efficacy of Refacto (St. Louis-derived active substance) in patients with haemophilia. Haemophilia. 2005;11:444-451.
26. Rosendaal FR, Nieuwenhuis HK, van den Berg HM, et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood. 1993;81: 2180-2186.
27. Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Thromb Haemost. 1998;79:872-875.